Clinical Trials

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01496976 2025-12-19

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

45 enrolled 12 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01258933 2025-10-01

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

4 enrolled 7 charts

Phase 2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

53 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01437709 2025-02-28

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

30 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

19 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01243190 2024-09-19

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

44 enrolled 7 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

4 enrolled 11 charts

Burkitt Lymphoma

NCT02199184 2024-06-11

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

14 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01527149 2024-02-07

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

37 enrolled 19 charts

Lymphoma, Mantle-Cell

NCT01145209 2023-11-28

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

32 enrolled 16 charts

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04189588 2023-10-06

versus

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase 2 Unknown

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02710643 2022-06-21

FIL_MIRO

110 enrolled

Lymphoma, Lymphoma, Follicular

NCT01481272 2021-12-27

PLRG8

77 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01190449 2021-08-18

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

51 enrolled 7 charts

Lymphoma, Lymphoma, Follicular

NCT01444716 2021-07-26

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

34 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01613300 2021-05-26

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

33 enrolled

Disease, Lymphoma, B-Cell

NCT01363128 2021-05-03

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

72 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

29 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01329900 2020-07-08

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

50 enrolled 7 charts

Lymphoma

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

66 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01532700 2019-09-24

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

28 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical hematologyLymphoidOther hematologic neoplasm

36 enrolled 7 charts

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01024010 2018-09-18

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

82 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT02419469 2018-06-11

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

1 enrolled 4 charts

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01191190 2018-05-08

CRC027

21 enrolled 12 charts

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01171378 2018-04-25

CHOP-OR

43 enrolled

Lymphoma, Non-Hodgkin

NCT01626352 2017-11-22

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

22 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT01848145 2017-06-06

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

34 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00811733 2017-05-30

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

37 enrolled 25 charts

Waldenstrom Macroglobulinemia

NCT01077622 2017-05-30

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

10 enrolled 35 charts

Leukemia, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

99 enrolled 27 charts

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01113632 2016-09-20

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

77 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01809847 2016-09-19

Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

20 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01536067 2016-06-10

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

3 enrolled 4 charts

Waldenstrom Macroglobulinemia

NCT02412267 2016-03-23

DLBL

17 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01195766 2016-02-24

Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

64 enrolled

Hodgkin Disease, Lymphoma

NCT01010568 2015-12-15

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

10 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01187303 2015-11-02

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

28 enrolled

Hodgkin Disease

NCT01263418 2015-10-12

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Phase 2 Withdrawn

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT01376713 2015-10-06

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

10 enrolled

Dermatologic

Melanoma

NCT01119794 2015-08-26

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

10 enrolled 7 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

10 enrolled 52 charts

Leukemia, B-Cell

NCT00622388 2015-07-24

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

81 enrolled 18 charts

Lymphoma, Large B-Cell, Diffuse

NCT01310101 2015-02-03

Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia

33 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01397591 2014-07-30

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

3 enrolled 6 charts